This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harrop, R. Articles by Carroll, M. W. Search for Related Content PubMed PubMed Citation Articles by Harrop, R. Articles by Carroll, M. W.

Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Induces Immune Responses which Correlate with Disease Control: A Phase I/II Trial

Authors' Affiliations: ¹ Oxford BioMedica (UK) Ltd., The Medawar Centre, Oxford Science Park, Oxford, United Kingdom and ² The Christie Hospital, Withington, Manchester, United Kingdom

Requests for reprints: Richard Harrop, Oxford BioMedica (UK) Ltd., The Medawar Centre, Oxford Science Park, Oxford OX4 4GA, United Kingdom. Phone: 44-1865-783000; Fax: 44-1865-783001; E-mail: r.harrop{at}oxfordbiomedica.co.uk.

Purpose: The highly attenuated strain of vaccinia virus, modified vaccinia Ankara (MVA), encoding the tumor antigen 5T4 (termed TroVax), has been evaluated in an open-label phase I/II study in colorectal cancer patients. The primary objectives were to assess the safety and immunogenicity of ascending doses of TroVax and to determine the biodistribution of the vector.

Experimental Design: TroVax was given to 22 patients with metastatic colorectal cancer. Seventeen patients received doses of TroVax ranging from 5 x 10⁷ up to 5 x 10⁸ plaque-forming units at 0, 4, and 8 weeks and were considered to be evaluable for assessment of immunologic responses. Both antibody and cellular responses specific for the tumor antigen 5T4 and the viral vector were monitored throughout the study.

Results: TroVax was well tolerated in all patients with no serious adverse events attributed to vaccination. Of 17 evaluable patients, 16 showed 5T4-specific cellular responses whereas 14 had detectable antibody levels following vaccination. TroVax was able to boost 5T4-specific immune responses in the presence of MVA neutralizing antibodies. Periods of disease stabilization ranging from 3 to 18 months were observed in five patients, all of whom mounted 5T4-specific immune responses. Furthermore, statistical analysis showed a positive association between the development of a 5T4 (but not MVA) antibody response and patient survival or time to disease progression.

Conclusion: These data indicate that vaccination with TroVax is safe and well tolerated and that immune responses to 5T4 can be induced without any evidence of autoimmune toxicity. Furthermore, 5T4-specific antibody responses correlate with evidence of disease control.

This article has been cited by other articles:

				A. E. Snook, P. Li, B. J. Stafford, E. J. Faul, L. Huang, R. C. Birbe, A. Bombonati, S. Schulz, M. J. Schnell, L. C. Eisenlohr, et al. Lineage-Specific T-Cell Responses to Cancer Mucosa Antigen Oppose Systemic Metastases without Mucosal Inflammatory Disease Cancer Res., April 15, 2009; 69(8): 3537 - 3544. [Abstract] [Full Text] [PDF]

				W. Kastenmuller, G. Gasteiger, L. Stross, D. H. Busch, and I. Drexler Cutting Edge: Mucosal Application of a Lyophilized Viral Vector Vaccine Confers Systemic and Protective Immunity toward Intracellular Pathogens J. Immunol., March 1, 2009; 182(5): 2573 - 2577. [Abstract] [Full Text] [PDF]

				R. J. Amato, W. Shingler, S. Naylor, J. Jac, J. Willis, S. Saxena, J. Hernandez-McClain, and R. Harrop Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial Clin. Cancer Res., November 15, 2008; 14(22): 7504 - 7510. [Abstract] [Full Text] [PDF]

				W. H. Shingler, P. Chikoti, S. M. Kingsman, and R. Harrop Identification and functional validation of MHC class I epitopes in the tumor-associated antigen 5T4 Int. Immunol., August 1, 2008; 20(8): 1057 - 1066. [Abstract] [Full Text] [PDF]

				G. Gasteiger, W. Kastenmuller, R. Ljapoci, G. Sutter, and I. Drexler Cross-Priming of Cytotoxic T Cells Dictates Antigen Requisites for Modified Vaccinia Virus Ankara Vector Vaccines J. Virol., November 1, 2007; 81(21): 11925 - 11936. [Abstract] [Full Text] [PDF]

				S. Guerra, J. L. Najera, J. M. Gonzalez, L. A. Lopez-Fernandez, N. Climent, J. M. Gatell, T. Gallart, and M. Esteban Distinct Gene Expression Profiling after Infection of Immature Human Monocyte-Derived Dendritic Cells by the Attenuated Poxvirus Vectors MVA and NYVAC J. Virol., August 15, 2007; 81(16): 8707 - 8721. [Abstract] [Full Text] [PDF]

				R. Harrop, N. Drury, W. Shingler, P. Chikoti, I. Redchenko, M. W. Carroll, S. M. Kingsman, S. Naylor, A. Melcher, J. Nicholls, et al. Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Chemotherapy Induces Potent Immune Responses Clin. Cancer Res., August 1, 2007; 13(15): 4487 - 4494. [Abstract] [Full Text] [PDF]